Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.

@article{Tanosaki1994DoseEO,
  title={Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.},
  author={Ryuji Tanosaki and Sanshiro Okamoto and Nobuharu Akatsuka and Akihiro Ishida and N Michikawa and Yuji Masuda and Hisashi Uchida and Makoto Murata and Masahiro Kizaki and Yasuharu Ikeda},
  journal={Cancer},
  year={1994},
  volume={74 7},
  pages={1939-44}
}
BACKGROUND Several uncontrolled trials have suggested that dose intensity of chemotherapy is a crucial determinant of treatment outcome for patients with non-Hodgkin's lymphoma (NHL). To explore the possibility of increasing dose intensity, a dose-escalation study of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) using recombinant human… CONTINUE READING